Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries.

Keystone EC, Rampakakis E, Movahedi M, Cesta A, Stutz M, Sampalis JS, Nantel F, Maslova K, Bombardier C.

J Rheumatol. 2019 Jul 1. pii: jrheum.190102. doi: 10.3899/jrheum.190102. [Epub ahead of print]

PMID:
31263067
2.

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis.

Takacs P, Lathia U, Shin J, Nantel F.

Patient Prefer Adherence. 2019 Jan 18;13:157-163. doi: 10.2147/PPA.S186776. eCollection 2019.

3.

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.

Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ, Nantel F.

Rheumatology (Oxford). 2019 Mar 1;58(3):522-526. doi: 10.1093/rheumatology/key359.

PMID:
30517715
4.

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.

Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K.

BMJ Open. 2017 Sep 18;7(9):e015872. doi: 10.1136/bmjopen-2017-015872.

5.

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.

Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, Kelsall J, Kapur S, Rampakakis E, Psaradellis E, Lehman AJ, Nantel F, Osborne B, Tkaczyk C.

BMJ Open. 2017 Aug 30;7(8):e016619. doi: 10.1136/bmjopen-2017-016619.

6.

Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis.

Lathia U, Ewara EM, Nantel F.

Patient Prefer Adherence. 2017 Jul 6;11:1133-1142. doi: 10.2147/PPA.S137206. eCollection 2017.

7.

Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.

Rahman P, Choquette D, Bensen WG, Khraishi M, Chow A, Zummer M, Shaikh S, Sheriff M, Dixit S, Sholter D, Psaradellis E, Sampalis JS, Letourneau V, Lehman AJ, Nantel F, Rampakakis E, Otawa S, Shawi M.

BMJ Open. 2016 Apr 5;6(4):e009661. doi: 10.1136/bmjopen-2015-009661.

8.

Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population.

Haraoui B, Jovaisas A, Bensen WG, Faraawi R, Kelsall J, Dixit S, Rodrigues J, Sheriff M, Rampakakis E, Sampalis JS, Lehman AJ, Otawa S, Nantel F, Shawi M.

RMD Open. 2015 Apr 29;1(1):e000078. doi: 10.1136/rmdopen-2015-000078. eCollection 2015.

9.

Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.

Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F.

J Rheumatol. 2015 Jul;42(7):1105-11. doi: 10.3899/jrheum.140538. Epub 2015 Jun 15.

10.

Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.

Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, Kelsall JT, Lehman AJ, Shawi M, Khalil H, Nantel F, Rampakakis E, Sampalis JS, Otawa S.

Arthritis Care Res (Hoboken). 2014 Aug;66(8):1142-51. doi: 10.1002/acr.22290.

11.

Bradykinin B(1) receptor antagonist R954 inhibits eosinophil activation/proliferation/migration and increases TGF-beta and VEGF in a murine model of asthma.

Vasquez-Pinto LM, Nantel F, Sirois P, Jancar S.

Neuropeptides. 2010 Apr;44(2):107-13. doi: 10.1016/j.npep.2009.11.001. Epub 2009 Dec 3.

PMID:
19962193
12.

Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats.

Daull P, Blouin A, Belleville K, Beaudoin M, Arsenault D, Leonard H, Sirois P, Nantel F, Jeng AY, Battistini B.

Exp Biol Med (Maywood). 2006 Jun;231(6):830-3.

PMID:
16741007
13.

The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601.

Daull P, Blouin A, Beaudoin M, Gadbois S, Belleville K, Cayer J, Berthiaume N, Sirois P, Nantel F, Jeng AY, Battistini B.

Exp Biol Med (Maywood). 2006 Jun;231(6):824-9.

PMID:
16741006
14.

The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats.

Daull P, Lepage R, Benrezzak O, Cayer J, Beaudoin M, Belleville K, Blouin A, Sirois P, Nantel F, Jeng AY, Battistini B.

Drug Chem Toxicol. 2006;29(2):183-202.

PMID:
16707327
15.
16.

Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.

Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B.

Am J Hypertens. 2005 Dec;18(12 Pt 1):1606-13.

PMID:
16364833
17.

Integrated in vivo pharmacology using an instrumented, unrestrained and conscious rat platform: application to rat models of diabetes.

Nantel F, Daull P, Berthiaume N, Duta DN, Blouin A, Cayer J, Beaudoin M, Belleville K, Benrezzak O, Sirois P, Battistini B.

J Pharmacol Toxicol Methods. 2006 May-Jun;53(3):248-55. Epub 2005 Nov 8.

PMID:
16280249
18.
19.

Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worchester rats: efficacy of a selective bradykinin B1 receptor antagonist.

Gabra BH, Benrezzak O, Pheng LH, Duta D, Daull P, Sirois P, Nantel F, Battistini B.

J Neuropathol Exp Neurol. 2005 Sep;64(9):782-9.

PMID:
16141788
20.
22.

Profile of endothelin isopeptides and markers of oxidative stress alongside the onset of streptozotocin-type I diabetes in rats.

Benrezzak O, Marois H, Daull P, Blouin A, Lepage R, Sirois P, Nantel F, Battistini B.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S168-72.

PMID:
15838272
23.

2,3-Diarylthiophenes as selective EP1 receptor antagonists.

Ducharme Y, Blouin M, Carrière MC, Chateauneuf A, Côté B, Denis D, Frenette R, Greig G, Kargman S, Lamontagne S, Martins E, Nantel F, O'Neill G, Sawyer N, Metters KM, Friesen RW.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1155-60.

PMID:
15686932
24.

Role of airway eosinophilia and eosinophil activation in Sephadex-induced inflammation.

Maghni K, Nantel F, Lanoue C, Cloutier S, Cristol JP, Cadieux A, Sirois P.

Inflammation. 2004 Aug;28(4):195-206.

PMID:
15673161
25.

Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist.

Lawson SR, Gabra BH, Guérin B, Neugebauer W, Nantel F, Battistini B, Sirois P.

Regul Pept. 2005 Jan 15;124(1-3):221-4.

PMID:
15544863
26.

Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa.

Nantel F, Fong C, Lamontagne S, Wright DH, Giaid A, Desrosiers M, Metters KM, O'Neill GP, Gervais FG.

Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):87-101.

PMID:
15165034
27.

The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat.

Martin JG, Suzuki M, Maghni K, Pantano R, Ramos-Barbón D, Ihaku D, Nantel F, Denis D, Hamid Q, Powell WS.

J Immunol. 2002 Oct 1;169(7):3963-9.

28.

Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP.

Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, Metters KM, O'neill GP.

J Allergy Clin Immunol. 2001 Dec;108(6):982-8.

PMID:
11742277
29.

Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey.

Lamontagne S, Meadows E, Luk P, Normandin D, Muise E, Boulet L, Pon DJ, Robichaud A, Robertson GS, Metters KM, Nantel F.

Brain Res. 2001 Nov 30;920(1-2):84-96.

PMID:
11716814
30.

Relationship of EP(1-4) prostaglandin receptors with rat hypothalamic cell groups involved in lipopolysaccharide fever responses.

Oka T, Oka K, Scammell TE, Lee C, Kelly JF, Nantel F, Elmquist JK, Saper CB.

J Comp Neurol. 2000 Dec 4;428(1):20-32.

PMID:
11058222
31.

Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract.

Northey A, Denis D, Cirino M, Metters KM, Nantel F.

Prostaglandins Other Lipid Mediat. 2000 Jul;62(2):145-56.

PMID:
10938408
32.

Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation.

Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters KM, Chan CC.

Br J Pharmacol. 1999 Oct;128(4):853-9.

33.

Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly.

Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A.

FEBS Lett. 1999 Sep 3;457(3):475-7.

34.

A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.

Wright DH, Nantel F, Metters KM, Ford-Hutchinson AW.

Eur J Pharmacol. 1999 Jul 14;377(1):101-15.

PMID:
10448933
35.

Coupling transcription to signaling pathways: cAMP and nuclear factor cAMP-responsive element modulator.

Monaco L, Lamas M, Tamai K, Lalli E, Zazopoulos E, Penna L, Nantel F, Foulkes NS, Mazzucchelli C, Sassone-Corsi P.

Adv Second Messenger Phosphoprotein Res. 1997;31:63-74. Review. No abstract available.

PMID:
9344242
36.

Coupling signalling pathways to transcriptional control: nuclear factors responsive to cAMP.

Tamai KT, Monaco L, Nantel F, Zazopoulos E, Sassone-Corsi P.

Recent Prog Horm Res. 1997;52:121-39; discussion 139-40. Review.

PMID:
9238850
37.

CREM: a transcriptional master switch during the spermatogenesis differentiation program.

Nantel F, Sassone-Corsi P.

Front Biosci. 1996 Sep 1;1:d266-9.

PMID:
9159233
38.

CREM: a master-switch in the transcriptional response to cAMP.

Lamas M, Monaco L, Zazopoulos E, Lalli E, Tamai K, Penna L, Mazzucchelli C, Nantel F, Foulkes NS, Sassone-Corsi P.

Philos Trans R Soc Lond B Biol Sci. 1996 Apr 29;351(1339):561-7. Review.

PMID:
8735279
39.
40.

Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice.

Nantel F, Monaco L, Foulkes NS, Masquilier D, LeMeur M, Henriksén K, Dierich A, Parvinen M, Sassone-Corsi P.

Nature. 1996 Mar 14;380(6570):159-62.

PMID:
8600390
41.

The nuclear response to cAMP: role of transcription factor CREM.

Lalli E, Lee JS, Lamas M, Tamai K, Zazopoulos E, Nantel F, Penna L, Foulkes NS, Sassone-Corsi P.

Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29;351(1336):201-9. Review.

PMID:
8650267
42.

Characterization of the vasorelaxant activity of tyramine and other phenylethylamines in rat aorta.

Varma DR, Deng XF, Chemtob S, Nantel F, Bouvier M.

Can J Physiol Pharmacol. 1995 Jun;73(6):742-6.

PMID:
7585347
43.

Functional effects of long-term activation on human beta 2- and beta 3-adrenoceptor signalling.

Nantel F, Bouvier M, Strosberg AD, Marullo S.

Br J Pharmacol. 1995 Mar;114(5):1045-51.

44.

Variability in the regulation of beta-adrenoceptor subtypes.

Marullo S, Nantel F, Strosberg AD, Bouvier M.

Biochem Soc Trans. 1995 Feb;23(1):126-9. Review. No abstract available.

PMID:
7758687
45.

Cell-specific down-regulation of the beta 3-adrenergic receptor.

Nantel F, Marullo S, Krief S, Strosberg AD, Bouvier M.

J Biol Chem. 1994 May 6;269(18):13148-55.

46.

Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.

Suzuki T, Nantel F, Bonin H, Valiquette M, Bouvier M.

J Pharmacol Exp Ther. 1993 Nov;267(2):785-90.

PMID:
7902433
47.

The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization.

Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, Marullo S.

Mol Pharmacol. 1993 Apr;43(4):548-55.

PMID:
8386307
48.

Distinct regulation of beta 1- and beta 2-adrenergic receptors in Chinese hamster fibroblasts.

Suzuki T, Nguyen CT, Nantel F, Bonin H, Valiquette M, Frielle T, Bouvier M.

Mol Pharmacol. 1992 Mar;41(3):542-8.

PMID:
1347641
49.

Pharmacological evaluation of the angiotensin, kinin, and neurokinin receptors on the rabbit vena cava.

Nantel F, Rouissi N, Rhaleb NE, Jukic D, Regoli D.

J Cardiovasc Pharmacol. 1991 Sep;18(3):398-405.

PMID:
1720840
50.

New highly potent bradykinin B2 receptor antagonists.

Regoli D, Rhaleb NE, Tousignant C, Rouissi N, Nantel F, Jukic D, Drapeau G.

Agents Actions. 1991 Sep;34(1-2):138-41.

PMID:
1665287

Supplemental Content

Loading ...
Support Center